Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling

Table 3

Tumor type and clinician and MP-guided therapy recommendation, MP results, and clinical outcomes: prior standard first-line therapy group (PST).

Tumor location	Prior lines	Next best treatment: clinician-defined	Next best treatment: MP-defined	Clinical observations	Biomarkers with/without benefit	Chemotherapy versus biological/targeted therapy	PFS ratio
Lung	1	Docetaxel	Carboplatin + nab-paclitaxel	CB	5/6	4 versus 0	0.65
Pancreas (adenocarcinoma)	1	FOLFIRINOX	FOLFIRINOX	P	5/7	8 versus 0	NA
Melanoma	1		Fotemustine	P	7/14	7 versus 0	0.72
Lung (small cell carcinoma)	1		FOLFIRI	CB	5/10	8 versus 1	0.80
Gall bladder	1	Epirubicin + cisplatin + 5-FU	FOLFOX	P	3/10	7 versus 0	1.64
Lung (small cell carcinoma)	1	Docetaxel	Cetuximab + FOLFIRI	P	6/3	9 versus 1	NA
Gastrointestinal (adenocarcinoma)	1	Carboplatin + nab-paclitaxel	FOLFIRI	CB	7/15	11 versus 0	1.5
Totals				CB = 3; = 4	38/65	54 versus 2

CB = clinical benefit (QOL/PS/general symptoms/weight and imaging results improved or stable); NA = not available; P = progression (QOL/PS/general symptoms/weight and imaging results declined or deteriorated).
Ratio of PFS with therapy suggested by MP versus that with prior line of therapy.
FOLFIRI, irinotecan + 5-FU + folinic acid; FOLFOX, 5-FU + folinic acid + oxaliplatin; FOLFIRINOX, irinotecan + 5-FU + folinic acid + oxaliplatin; PFS, progression-free survival; PS, performance status; QOL, quality of life.